Michael M Chen - JoVE Visualize

Showing results (21-30 of 33) with videos related to

Pageof 4

Sort By:

Journal of Cancer|August 19, 2017

A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection (KLTi) plus Gemcitabine versus Gemcitabine in Patients with Advanced Pancreatic CancerLee S Schwartzberg, Francis P Arena, Bryan J Bienvenu, et al.

Anti-Cancer Drugs|November 30, 2011

Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancerHenry L Gomez, Manuel Philco, Patricia Pimentel, et al.

Muscle & Nerve|March 18, 2014

Tirasemtiv amplifies skeletal muscle response to nerve activation in humansRichard Hansen, Khalil G Saikali, Willis Chou, et al.

Rheumatology and Therapy|March 18, 2024

Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical TrialAndrew Östör, Filip Van den Bosch, Kim Papp, et al.

American Journal of Clinical Dermatology|July 29, 2025

Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial ResultsKim A Papp, Mark G Lebwohl, Lluís Puig, et al.

JACC. Heart Failure|December 3, 2014

Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and anginaBarry H Greenberg, Willis Chou, Khalil G Saikali, et al.

Allergy and Asthma Proceedings|December 6, 2021

COVID-19 vaccine-related presumed allergic reactions and second dose administration by using a two-step graded protocolGayatri B Patel, Krishan D Chhiba, Michael M Chen, et al.

Lancet (London, England)|August 23, 2011

Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man studyJohn R Teerlink, Cyril P Clarke, Khalil G Saikali, et al.

Alcohol (Fayetteville, N.Y.)|December 4, 2014

Alcohol and inflammatory responses: summary of the 2013 Alcohol and Immunology Research Interest Group (AIRIG) meetingNiya L Morris, Jill A Ippolito, Brenda J Curtis, et al.

Journal of the American Academy of Dermatology|August 8, 2023

Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-upKim A Papp, Andrew Blauvelt, Lluís Puig, et al.

Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:

Pageof 4

Journal of Cancer|August 19, 2017

A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection (KLTi) plus Gemcitabine versus Gemcitabine in Patients with Advanced Pancreatic CancerLee S Schwartzberg, Francis P Arena, Bryan J Bienvenu, et al.

Anti-Cancer Drugs|November 30, 2011

Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancerHenry L Gomez, Manuel Philco, Patricia Pimentel, et al.

Muscle & Nerve|March 18, 2014

Tirasemtiv amplifies skeletal muscle response to nerve activation in humansRichard Hansen, Khalil G Saikali, Willis Chou, et al.

Rheumatology and Therapy|March 18, 2024

Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical TrialAndrew Östör, Filip Van den Bosch, Kim Papp, et al.

American Journal of Clinical Dermatology|July 29, 2025

Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial ResultsKim A Papp, Mark G Lebwohl, Lluís Puig, et al.

JACC. Heart Failure|December 3, 2014

Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and anginaBarry H Greenberg, Willis Chou, Khalil G Saikali, et al.

Allergy and Asthma Proceedings|December 6, 2021

COVID-19 vaccine-related presumed allergic reactions and second dose administration by using a two-step graded protocolGayatri B Patel, Krishan D Chhiba, Michael M Chen, et al.

Lancet (London, England)|August 23, 2011

Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man studyJohn R Teerlink, Cyril P Clarke, Khalil G Saikali, et al.

Alcohol (Fayetteville, N.Y.)|December 4, 2014

Alcohol and inflammatory responses: summary of the 2013 Alcohol and Immunology Research Interest Group (AIRIG) meetingNiya L Morris, Jill A Ippolito, Brenda J Curtis, et al.

Journal of the American Academy of Dermatology|August 8, 2023

Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-upKim A Papp, Andrew Blauvelt, Lluís Puig, et al.

Pageof 4